Open AccessEffects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs
Author(s) -
Seamus Kent,
Richard Haynes,
Jemma C. Hopewell,
Sarah Parish,
Alastair Gray,
Martin Landray,
Rory Collins,
Jane Armitage,
Borislava Mihaylova
Publication year - 2016
Publication title -
circulation cardiovascular quality and outcomes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.692
H-Index - 87
eISSN - 1941-7713
pISSN - 1941-7705
DOI - 10.1161/circoutcomes.115.002592
Subject(s) - niacin , medicine , adverse effect , quality of life (healthcare) , randomized controlled trial , placebo , alternative medicine , pathology , nursing
Extended-release niacin with laropiprant did not significantly reduce the risk of major vascular events and increased the risk of serious adverse events in Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE), but its net effects on health and healthcare costs are unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom